中国仓鼠卵巢细胞源乙型肝炎疫苗18-20年后的长期效力与回忆应答
2017年底在正定县七个社区对1997-1999年出生、主要接种三剂中国仓鼠卵巢细胞源乙型肝炎疫苗(CHO-HepB)的队列进行横断面调查,共纳入1352人。HBsAg、抗-HBs、抗-HBc阳性率分别为0.4%、74.5%、1.3%,各出生年份组间无显著差异(P>0.05)。初种后18-20年长期效力稳定,加强接种CHO-HepB后抗-HBs阳转率较高,但鉴于二十年无新发感染或携带者,似无必要加强接种。
要点
- 初种CHO-HepB后18-20年,HBsAg、抗-HBs、抗-HBc阳性率分别为0.4%、74.5%、1.3%,各出生年份组间无显著差异(P>0.05)。
- 1007名抗-HBs阳性者几何平均浓度(GMC)为191 mIU/ml;调查中未发现新发感染或携带者。
- 248名加强接种者中231人(93.1%)抗-HBs阳性,GMC为369 mIU/mL,且CHO-HepB加强组抗-HBs阳性率和GMC高于酿酒酵母-HepB加强组。
核心结论
- CHO-HepB初种后18-20年长期效力保持稳定,加强接种CHO-HepB后抗-HBs血清阳转率较高。
- 鉴于过去二十年无新发感染或携带者,似无必要进行乙型肝炎疫苗加强接种。
研究设计与样本
- 2017年底在正定县七个社区开展横断面调查,纳入1997-1999年出生、主要接种三剂CHO-HepB的出生队列。
- 采用化学发光法定量检测HBV血清学标志物,抗-HBs阴性者接种一剂HepB后评估回忆应答。
- 共纳入1352名参与者。
主要发现
- HBsAg、抗-HBs、抗-HBc阳性率分别为0.4%、74.5%、1.3%,各出生年份组间HBV标志物无显著差异(P>0.05)。
- 1007名抗-HBs阳性者的抗-HBs几何平均浓度(GMC)为191 mIU/ml。
- 调查中未发现新发感染或携带者;结合同一出生队列既往三次调查,HBsAg、抗-HBs、抗-HBc阳性率在CHO-HepB接种后二十年基本不变。
- 248名接受加强接种者中231人(93.1%)抗-HBs阳性,GMC为369 mIU/mL。
- CHO-HepB加强组的抗-HBs阳性率和GMC高于酿酒酵母-HepB加强组。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To evaluate the long-term efficacy and anamnestic response of Chinese hamster ovary (CHO) cell-derived hepatitis B vaccine (CHO-HepB) after 18-20 years, a cross-sectional survey was conducted in seven communities in Zhengding County at the end of 2017. The birth cohort 1997-1999 vaccinated primarily with three doses of CHO-HepB were enrolled in the survey. The HBV serological markers were quantified using the Chemiluminescence method. The infection status of HBsAg-positive participants was determined by comparing their results with the previous data. For those with an anti-HBs antibody negative, the anamnestic response was evaluated by measuring anti-HBs antibody concentrations following a dose of HepB administration. A total of 1352 participants were enrolled, with the prevalence of HBsAg, anti-HBs, and anti-HBc being 0.4 %, 74.5 %, and 1.3 %, respectively. There was no significant difference in the HBV markers (HBsAg, anti-HBs and anti-HBc) between birth-year groups (P > 0.05). The geometric mean concentration (GMC) of anti-HBs antibodies among 1007 positive participants was 191 mIU/ml. No new infections or carriers were identified in the survey. Combined with the three previous surveys of the same birth cohort, the positive rates of HBsAg, anti-HBs, and anti-HBc remained largely unchanged over two decades following CHO-HepB vaccination. Of 248 participants who received a booster vaccination, 231 (93.1 %) showed an anti-HBs antibody positive with a GMC of 369 mIU/mL. Moreover, the positive rate and GMC of anti-HBs were higher in the CHO-HepB booster group compared to the Saccharomyces cerevisiae-HepB booster group. The long-term efficacy of the CHO-HepB remains stable for 18-20 years after primary vaccination, and a higher seroconversion rate of anti-HBs is observed following a booster vaccination of CHO-HepB. Given the absence of new infections or carriers over the past two decades, it appears unnecessary to administer a booster vaccination of HepB.
引用
- Su Q, Qiu F, Gao Z, et al. Long-term efficacy and anamnestic response of hepatitis B vaccine derived from Chinese hamster ovary cell after 18-20 years. Vaccine. 2025. PMID: 39787797. doi:10.1016/j.vaccine.2024.126655
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。